Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-03-31

Clinical Trial Update: Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating preoperative cisplatin and bevacizumab in ER-, PR-, HER2-negative breast cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bevacizumab (bevacizumab)
  • CISPLATIN (cisplatin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-03-31